Eramet S.A [ERA] vs ZCI Limited [CV] Detailed Stock Comparison
Eramet S.A
Euronext
Loading...
ZCI Limited
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Eramet S.A wins in 4 metrics, ZCI Limited wins in 11 metrics, with 0 ties. ZCI Limited appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Eramet S.A | ZCI Limited | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 105.50 | 2.50 | ZCI Limited |
| Price-to-Book Ratio | 1.43 | 0.16 | ZCI Limited |
| Debt-to-Equity Ratio | 140.34 | 29.90 | ZCI Limited |
| PEG Ratio | 5.32 | N/A | N/A |
| EV/EBITDA | 15.59 | -0.30 | ZCI Limited |
| Profit Margin (TTM) | -3.33% | 7.82% | ZCI Limited |
| Operating Margin (TTM) | -6.81% | -6.09% | ZCI Limited |
| Return on Equity | -6.50% | -7.78% | Eramet S.A |
| Return on Assets (TTM) | -0.09% | -3.51% | Eramet S.A |
| Free Cash Flow (TTM) | $-727.00M | N/A | N/A |
| Dividend Yield | 3.15% | N/A | N/A |
| 1-Year Return | -26.77% | 0.00% | ZCI Limited |
| Price-to-Sales Ratio (TTM) | 0.51 | 0.19 | ZCI Limited |
| Enterprise Value | $3.91B | $-8.66M | Eramet S.A |
| EV/Revenue Ratio | 1.34 | -0.17 | ZCI Limited |
| Revenue per Share (TTM) | $102 | $1 | Eramet S.A |
| Earnings per Share (Diluted) | $-3.37 | $0.08 | ZCI Limited |
| Beta (Stock Volatility) | 1.47 | 0.00 | ZCI Limited |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Eramet S.A vs ZCI Limited Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eramet S.A | 1.06% | 2.23% | 1.35% | 14.61% | -1.86% | -4.10% |
| ZCI Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eramet S.A | -26.77% | -35.32% | 152.03% | 53.50% | -38.69% | -38.69% |
| ZCI Limited | 0.00% | 0.00% | 0.00% | 0.00% | -31.03% | -31.03% |
News Based Sentiment: Eramet S.A vs ZCI Limited
Eramet S.A
News based Sentiment: NEGATIVE
September was a significantly negative month for Eramet, dominated by operational setbacks in Indonesia, a major ESG concern leading to exclusion from the Norwegian sovereign wealth fund, and credit downgrades. These events collectively signal a deteriorating outlook for the company and create substantial risks for investors.
ZCI Limited
News sentiment data is not available for ZCI Limited at this time.
Performance & Financial Health Analysis: Eramet S.A vs ZCI Limited
| Metric | ERA | CV |
|---|---|---|
| Market Information | ||
| Market Cap | €1.51B | €11.14M |
| Market Cap Category | Large cap | Small cap |
| 10 Day Avg. Volume | 65,908 | N/A |
| 90 Day Avg. Volume | 42,767 | N/A |
| Last Close | €52.65 | €0.20 |
| 52 Week Range | €38.74 - €73.25 | €0.20 - €0.20 |
| % from 52W High | -28.12% | 0.00% |
| All-Time High | €167.20 (Apr 16, 2018) | €0.29 (Jul 14, 2014) |
| % from All-Time High | -68.51% | -31.03% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.07% | 0.04% |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -0.03% | 0.08% |
| Operating Margin (TTM) | -0.07% | -0.06% |
| Return on Equity (TTM) | -0.07% | -0.08% |
| Debt to Equity (MRQ) | 140.34 | 29.90 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €36.47 | €1.22 |
| Cash per Share (MRQ) | €26.06 | €0.11 |
| Operating Cash Flow (TTM) | €-133,000,000 | €10.59M |
| Levered Free Cash Flow (TTM) | €-493,624,992 | €27.99M |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.15% | N/A |
| Last 12-Month Dividend | €1.51 | N/A |
Valuation & Enterprise Metrics Analysis: Eramet S.A vs ZCI Limited
| Metric | ERA | CV |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 105.50 | 2.50 |
| Forward P/E | 5.32 | N/A |
| PEG Ratio | 5.32 | N/A |
| Price to Sales (TTM) | 0.51 | 0.19 |
| Price to Book (MRQ) | 1.43 | 0.16 |
| Market Capitalization | ||
| Market Capitalization | €1.51B | €11.14M |
| Enterprise Value | €3.91B | €-8,659,605 |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.34 | -0.17 |
| Enterprise to EBITDA | 15.59 | -0.30 |
| Risk & Other Metrics | ||
| Beta | 1.47 | 0.00 |
| Book Value per Share (MRQ) | €36.47 | €1.22 |
Financial Statements Comparison: Eramet S.A vs ZCI Limited
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ERA | CV |
|---|---|---|
| Revenue/Sales | N/A | N/A |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | N/A |
| EBITDA | N/A | N/A |
| Pre-Tax Income | N/A | N/A |
| Income Tax | N/A | N/A |
| Net Income (Profit) | N/A | N/A |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ERA | CV |
|---|---|---|
| Cash & Equivalents | €595.00M | N/A |
| Total Current Assets | €2.14B | N/A |
| Total Current Liabilities | €1.39B | N/A |
| Long-Term Debt | €2.06B | N/A |
| Total Shareholders Equity | €1.76B | N/A |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | €6.97B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ERA | CV |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ERA | CV |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 65,908 | N/A |
| Average Daily Volume (90 Day) | 42,767 | N/A |
| Shares Outstanding | 28.58M | 55.68M |
| Float Shares | 9.39M | 55.65M |
| % Held by Insiders | 0.70% | N/A |
| % Held by Institutions | 0.13% | N/A |
Dividend Analysis & Yield Comparison: Eramet S.A vs ZCI Limited
| Metric | ERA | CV |
|---|---|---|
| Last 12-Month Dividend | €1.51 | N/A |
| Last 12-Month Dividend Yield | 3.15% | N/A |
| 3-Year Avg Annual Dividend | €2.17 | N/A |
| 3-Year Avg Dividend Yield | 2.79% | N/A |
| 3-Year Total Dividends | €6.51 | N/A |
| Ex-Dividend Date | Jun 02, 2025 | N/A |